HUTCHMED Highlights Positive Phase III SACHI Results in The Lancet for NSCLC Combination Therapy

summarizeZusammenfassung

The publication of the full Phase III SACHI trial results in The Lancet provides strong scientific validation for HUTCHMED's savolitinib and osimertinib combination therapy. The study demonstrated significant improvements in progression-free survival and objective response rates for patients with EGFR-mutated NSCLC with MET amplification, a challenging patient population. While the combination is already approved in China, this publication reinforces the drug's efficacy and safety profile, bolstering its global development prospects, including the ongoing SAFFRON trial for potential US FDA registration.

check_boxSchlusselereignisse

• Phase III SACHI Results Published in The Lancet

  The full results from the SACHI Phase III trial, evaluating the savolitinib and osimertinib combination for advanced NSCLC, were published in the prestigious medical journal, The Lancet.

• Significant Efficacy Demonstrated

  The trial met its primary endpoint, showing a median progression-free survival of 8.2 months for the combination therapy compared to 4.5 months for chemotherapy (HR 0.34; p<0.0001). The objective response rate was 58% versus 34%.

• Reinforces China Approval and Global Development

  The combination was already approved in China in June 2025 based on interim SACHI data. This publication provides robust scientific backing, supporting ongoing global development efforts like the SAFFRON trial for potential US FDA registration.

• Tolerable Safety Profile

  The safety profile of the savolitinib and osimertinib combination was found to be tolerable, with no new safety signals observed during the trial.

auto_awesomeAnalyse

The publication of the full Phase III SACHI trial results in The Lancet provides strong scientific validation for HUTCHMED's savolitinib and osimertinib combination therapy. The study demonstrated significant improvements in progression-free survival and objective response rates for patients with EGFR-mutated NSCLC with MET amplification, a challenging patient population. While the combination is already approved in China, this publication reinforces the drug's efficacy and safety profile, bolstering its global development prospects, including the ongoing SAFFRON trial for potential US FDA registration.